

**ASSET ACQUISITIONS AND DISPOSALS::COMPLETION OF PROPOSED ACQUISITION OF THE TRANCHE 1 SALE SHARES OF 23% IN ARDENCE PHARMA SDN BHD**

## Issuer &amp; Securities

## Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

## Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

## Stapled Security

No

## Announcement Details

## Announcement Title

Asset Acquisitions and Disposals

## Date &amp; Time of Broadcast

08-Nov-2023 20:12:57

## Status

New

## Announcement Sub Title

COMPLETION OF PROPOSED ACQUISITION OF THE TRANCHE 1 SALE SHARES OF 23% IN ARDENCE PHARMA SDN BHD

## Announcement Reference

SG231108OTHR3G8Y

## Submitted By (Co./ Ind. Name)

Lim See Wah

## Designation

Executive Chairman and CEO

## Description (Please provide a detailed description of the event in the box below)

Please refer to the attached.

This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: +65 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

## Attachments

[20231108 Hyphens Pharma - Project Cantik announcement Tranche 1 completion.pdf](#)





Hyphens Pharma International Limited  
16 Tai Seng Street, Level 4, Singapore 534138  
T: (65) 6338 8551 F: (65) 6338 8825 W: www.hyphensgroup.com  
Co. Reg. No.: 201735688C GST Reg. No.: 201735688C

---

**COMPLETION OF THE PROPOSED ACQUISITION OF THE TRANCHE 1 SALE SHARES OF 23% OF THE ISSUED AND PAID-UP ORDINARY SHARE CAPITAL IN ARDENCE PHARMA SDN BHD**

---

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in Company's announcement dated 17 October 2023 ("**Announcement**").*

The board of directors (the "**Board**" or "**Directors**") of the Company refers to the Announcement relating to the Proposed Acquisition and is pleased to announce that the Tranche 1 Completion has taken place on 8 November 2023. Accordingly, subsequent to the Tranche 1 Completion, the latest shareholding held by the Group in Ardence Pharma is 65%.

The Company will make further announcements to keep shareholders informed, as and when there are further material developments on the Proposed Acquisition in due course.

**BY ORDER OF THE BOARD**

**Lim See Wah**

Executive Chairman and Chief Executive Officer

8 November 2023

---

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) who can be contacted at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.*